63 related articles for article (PubMed ID: 1295470)
1. Mutant p53 product in patients with stage III cervical cancer.
Gitsch G; Kainz C; Joura E; Breitenecker G
Anticancer Res; 1992; 12(6B):2241-2. PubMed ID: 1295470
[TBL] [Abstract][Full Text] [Related]
2. Mutant p53 in patients with invasive cervical cancer stages IB to IIB.
Kainz C; Kohlberger P; Gitsch G; Sliutz G; Breitenecker G; Reinthaller A
Gynecol Oncol; 1995 May; 57(2):212-4. PubMed ID: 7729736
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical detection of mutant p53-suppressor gene product in patients with breast cancer: influence on metastasis-free survival.
Hanzal E; Gitsch G; Kohlberger P; Dadak C; Miechowiecka N; Breitenecker G
Anticancer Res; 1992; 12(6B):2325-9. PubMed ID: 1295480
[TBL] [Abstract][Full Text] [Related]
4. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer.
Kawasaki M; Nakanishi Y; Kuwano K; Yatsunami J; Takayama K; Hara N
Clin Cancer Res; 1997 Jul; 3(7):1195-200. PubMed ID: 9815799
[TBL] [Abstract][Full Text] [Related]
5. p53 and p21 expression in precancerous lesions and carcinomas of the uterine cervix: overexpression of p53 predicts poor disease outcome.
Huang LW; Chou YY; Chao SL; Chen TJ; Lee TT
Gynecol Oncol; 2001 Nov; 83(2):348-54. PubMed ID: 11606096
[TBL] [Abstract][Full Text] [Related]
6. Rearrangement of p53 gene with overexpressed p53 protein in primary cervical cancer.
Sahu GR; Nayak BK; Patnaik S; Parija T; Das BR
Oncol Rep; 2002; 9(2):433-7. PubMed ID: 11836622
[TBL] [Abstract][Full Text] [Related]
7. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
Ahnen DJ; Feigl P; Quan G; Fenoglio-Preiser C; Lovato LC; Bunn PA; Stemmerman G; Wells JD; Macdonald JS; Meyskens FL
Cancer Res; 1998 Mar; 58(6):1149-58. PubMed ID: 9515799
[TBL] [Abstract][Full Text] [Related]
8. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG
Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900
[TBL] [Abstract][Full Text] [Related]
9. p53 alterations are associated with improved prognosis in distal colonic carcinomas.
Soong R; Grieu F; Robbins P; Dix B; Chen D; Parsons R; House A; Iacopetta B
Clin Cancer Res; 1997 Aug; 3(8):1405-11. PubMed ID: 9815825
[TBL] [Abstract][Full Text] [Related]
10. Relation between p53 overexpression and established prognostic factors in breast cancer.
Davidoff AM; Herndon JE; Glover NS; Kerns BJ; Pence JC; Iglehart JD; Marks JR
Surgery; 1991 Aug; 110(2):259-64. PubMed ID: 1858036
[TBL] [Abstract][Full Text] [Related]
11. p53 protein overexpression in early stage endometrial cancer.
Kohlberger P; Gitsch G; Loesch A; Tempfer C; Kaider A; Reinthaller A; Kainz C; Breitenecker G
Gynecol Oncol; 1996 Aug; 62(2):213-7. PubMed ID: 8751552
[TBL] [Abstract][Full Text] [Related]
12. p53 protein expression in squamous cell carcinoma of the vulva.
Scheistrøen M; Tropé C; Pettersen EO; Nesland JM
Cancer; 1999 Mar; 85(5):1133-8. PubMed ID: 10091798
[TBL] [Abstract][Full Text] [Related]
13. Correlation between human papillomavirus positivity and p53 gene overexpression in adenocarcinoma of the uterine cervix.
Uchiyama M; Iwasaka T; Matsuo N; Hachisuga T; Mori M; Sugimori H
Gynecol Oncol; 1997 Apr; 65(1):23-9. PubMed ID: 9103386
[TBL] [Abstract][Full Text] [Related]
14. Deregulated p21(WAF1) overexpression impacts survival of surgically resected esophageal squamous cell carcinoma patients.
Goan YG; Hsu HK; Chang HC; Chou YP; Chiang KH; Cheng JT
Ann Thorac Surg; 2005 Sep; 80(3):1007-16. PubMed ID: 16122475
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D receptor (VDR) expression is not a prognostic factor in cervical cancer.
Friedrich M; Meyberg R; Axt-Fliedner R; Villena-Heinsen C; Tilgen W; Schmidt W; Reichrath J
Anticancer Res; 2002; 22(1A):299-304. PubMed ID: 12017307
[TBL] [Abstract][Full Text] [Related]
16. p53 as a prognostic factor for stage III serous adenocarcinoma of the ovary.
Daponte A; Guidozi F; Tiltman AJ; Marineanu A; Taylor L
Anticancer Res; 1999; 19(3B):2387-9. PubMed ID: 10472362
[TBL] [Abstract][Full Text] [Related]
17. p53 gene alterations and human papillomavirus type 16 infection in early stages of cervical carcinoma in Serbia.
Malisic E; Jankovic R; Majkic M; Dobricic J; Radulovic S
J BUON; 2008; 13(4):525-32. PubMed ID: 19145674
[TBL] [Abstract][Full Text] [Related]
18. Quantification of p53 in epithelial ovarian cancer.
Geisler JP; Geisler HE; Wiemann MC; Givens SS; Zhou Z; Miller GA
Gynecol Oncol; 1997 Sep; 66(3):435-8. PubMed ID: 9299258
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Havrilesky L; Darcy kM; Hamdan H; Priore RL; Leon J; Bell J; Berchuck A;
J Clin Oncol; 2003 Oct; 21(20):3814-25. PubMed ID: 14551300
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.
Hirai K; Koizumi K; Haraguchi S; Hirata T; Mikami I; Fukushima M; Yamagishi S; Kawashima T; Okada D; Shimizu K; Kawamoto M
Ann Thorac Surg; 2005 Jan; 79(1):248-53. PubMed ID: 15620951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
